Literature DB >> 31709451

Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series.

Adrien Mareschal1, Eve Puzenat, François Aubin.   

Abstract

Entities:  

Keywords:  atopic dermatitis; children; dupilumab; paediatry

Mesh：

Substances：

Year:  2020        PMID： 31709451      PMCID： PMC9128934          DOI： 10.2340/00015555-3368

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  12 in total

Review 1.  Targeting key proximal drivers of type 2 inflammation in disease.

Authors:  Namita A Gandhi; Brandy L Bennett; Neil M H Graham; Gianluca Pirozzi; Neil Stahl; George D Yancopoulos
Journal:  Nat Rev Drug Discov       Date:  2015-10-16       Impact factor: 84.694

2.  Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.

Authors:  Sarah Faiz; Jonathan Giovannelli; Céline Podevin; Marie Jachiet; Jean-David Bouaziz; Ziad Reguiai; Audrey Nosbaum; Audrey Lasek; Marie-Christine Ferrier le Bouedec; Aurélie Du Thanh; Nadia Raison-Peyron; Florence Tetart; Anne-Bénédicte Duval-Modeste; Laurent Misery; François Aubin; Anne Dompmartin; Cécile Morice; Catherine Droitcourt; Angèle Soria; Jean-Philippe Arnault; Juliette Delaunay; Emmanuel Mahé; Marie-Aleth Richard; Amélie Schoeffler; Jean-Philippe Lacour; Edouard Begon; Amélie Walter-Lepage; Anne-Sophie Dillies; Sandrine Rappelle-Duruy; Stéphane Barete; Nathalia Bellon; Nathalie Bénéton; Aude Valois; Sébastien Barbarot; Julien Sénéchal; Delphine Staumont-Sallé
Journal:  J Am Acad Dermatol       Date:  2019-02-27       Impact factor: 11.527

3.  Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Authors:  Eric L Simpson; Thomas Bieber; Emma Guttman-Yassky; Lisa A Beck; Andrew Blauvelt; Michael J Cork; Jonathan I Silverberg; Mette Deleuran; Yoko Kataoka; Jean-Philippe Lacour; Külli Kingo; Margitta Worm; Yves Poulin; Andreas Wollenberg; Yuhwen Soo; Neil M H Graham; Gianluca Pirozzi; Bolanle Akinlade; Heribert Staudinger; Vera Mastey; Laurent Eckert; Abhijit Gadkari; Neil Stahl; George D Yancopoulos; Marius Ardeleanu
Journal:  N Engl J Med       Date:  2016-09-30       Impact factor: 91.245

4.  Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

Authors:  Lisa A Beck; Diamant Thaçi; Jennifer D Hamilton; Neil M Graham; Thomas Bieber; Ross Rocklin; Jeffrey E Ming; Haobo Ren; Richard Kao; Eric Simpson; Marius Ardeleanu; Steven P Weinstein; Gianluca Pirozzi; Emma Guttman-Yassky; Mayte Suárez-Fariñas; Melissa D Hager; Neil Stahl; George D Yancopoulos; Allen R Radin
Journal:  N Engl J Med       Date:  2014-07-10       Impact factor: 91.245

5.  Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

Authors:  Diamant Thaçi; Eric L Simpson; Lisa A Beck; Thomas Bieber; Andrew Blauvelt; Kim Papp; Weily Soong; Margitta Worm; Jacek C Szepietowski; Howard Sofen; Makoto Kawashima; Richard Wu; Steven P Weinstein; Neil M H Graham; Gianluca Pirozzi; Ariel Teper; E Rand Sutherland; Vera Mastey; Neil Stahl; George D Yancopoulos; Marius Ardeleanu
Journal:  Lancet       Date:  2015-10-08       Impact factor: 79.321

6.  Long-term off-label dupilumab in pediatric atopic dermatitis: A case series.

Authors:  Alison D Treister; Peter A Lio
Journal:  Pediatr Dermatol       Date:  2018-10-18       Impact factor: 1.588

7.  Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.

Authors:  Lawrence F Eichenfield; Thomas Bieber; Lisa A Beck; Eric L Simpson; Diamant Thaçi; Marjolein de Bruin-Weller; Mette Deleuran; Jonathan I Silverberg; Carlos Ferrandiz; Regina Fölster-Holst; Zhen Chen; Neil M H Graham; Gianluca Pirozzi; Bolanle Akinlade; George D Yancopoulos; Marius Ardeleanu
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

8.  Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.

Authors:  M J Cork; D Thaçi; L F Eichenfield; P D Arkwright; T Hultsch; J D Davis; Y Zhang; X Zhu; Z Chen; M Li; M Ardeleanu; A Teper; B Akinlade; A Gadkari; L Eckert; M A Kamal; M Ruddy; N M H Graham; G Pirozzi; N Stahl; A T DiCioccio; A Bansal
Journal:  Br J Dermatol       Date:  2019-10-08       Impact factor: 9.302

9.  Conjunctivitis in dupilumab clinical trials.

Authors:  B Akinlade; E Guttman-Yassky; M de Bruin-Weller; E L Simpson; A Blauvelt; M J Cork; E Prens; P Asbell; E Akpek; J Corren; C Bachert; I Hirano; J Weyne; A Korotzer; Z Chen; T Hultsch; X Zhu; J D Davis; L Mannent; J D Hamilton; A Teper; H Staudinger; E Rizova; G Pirozzi; N M H Graham; B Shumel; M Ardeleanu; A Wollenberg
Journal:  Br J Dermatol       Date:  2019-05-07       Impact factor: 9.302

10.  Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion.

Authors:  J P Thyssen; M S de Bruin-Weller; A S Paller; Y A Leshem; C Vestergaard; M Deleuran; A M Drucker; R Foelster-Holst; C Traidl-Hoffmann; K Eyerich; A Taieb; J C Su; T Bieber; M J Cork; L F Eichenfield; E Guttman-Yassky; A Wollenberg
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-05-06       Impact factor: 6.166
View more
  4 in total

1.  Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real-life study.

Authors:  Luca Mastorino; Riccardo Viola; Michele Panzone; Gianluca Avallone; Giuseppe Gallo; Michela Ortoncelli; Giovanni Cavaliere; Pietro Quaglino; Simone Ribero
Journal:  Dermatol Ther       Date:  2021-09-02       Impact factor: 3.858

2.  Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis.

Authors:  Tamara Quint; Patrick M Brunner; Christoph Sinz; Irene Steiner; Robin Ristl; Kornelia Vigl; Susanne Kimeswenger; Katharina Neubauer; Detlev Pirkhammer; Martin Zikeli; Wolfram Hoetzenecker; Norbert Reider; Christine Bangert
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

3.  Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.

Authors:  L Stingeni; L Bianchi; E Antonelli; E S Caroppo; S M Ferrucci; M Ortoncelli; G Fabbrocini; E Nettis; D Schena; M Napolitano; M Gola; L Bonzano; M Rossi; A Belloni Fortina; A Balato; K Peris; C Foti; F Guarneri; M Romanelli; C Patruno; P Savoia; M C Fargnoli; F Russo; E Errichetti; T Bianchelli; L Bianchi; G Pellacani; C Feliciani; A Offidani; M Corazza; G Micali; N Milanesi; G Malara; A Chiricozzi; M Tramontana; K Hansel
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-04-22       Impact factor: 9.228

4.  Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic.

Authors:  K Hansel; C Patruno; E Antonelli; G Dal Bello; M Napolitano; G Fabbrocini; T Grieco; G Pellacani; M C Fargnoli; M Esposito; V Piras; M Zucca; G Girolomoni; L Stingeni
Journal:  Clin Exp Dermatol       Date:  2021-08-24       Impact factor: 4.481
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.